E1199 — Adjuvant Paclitaxel and Docetaxel, Weekly Versus Every-3-Weeks, After Doxorubicin-Cyclophosphamide in Node-Positive/High-Risk Breast Cancer

Phase 3 · 2008 · Breast Cancer

Design

2x2 design after AC: paclitaxel or docetaxel, given weekly or every 3 weeks.

Population

Resected node-positive or high-risk node-negative breast cancer.

Primary Endpoint

disease-free survival (DFS)

Key Result

Weekly paclitaxel improved DFS (HR 1.27 for standard vs weekly) and OS vs every-3-week paclitaxel; docetaxel every 3 weeks improved DFS.

Guideline Impact

Weekly paclitaxel adopted as a standard adjuvant taxane schedule in NCCN guidelines